<DOC>
	<DOCNO>NCT02974803</DOCNO>
	<brief_summary>Dabrafenib trametinib drug usually give treatment melanoma . Combinations dabrafenib trametinib also study use together show increase tumour shrinkage animal compare either drug alone . Dabrafenib trametinib also show potential penetrate blood-brain-barrier give together effect brain metastasis . Giving drug time give brain stereotactic radiosurgery ( SRS ) may also prefer patient brain metastasis</brief_summary>
	<brief_title>Concurrent Dabrafenib Trametinib With Sterotactic Radiation Patients With BRAF Mutation-Positive Malignant Melanoma Brain Metastases</brief_title>
	<detailed_description>The purpose study find effect give dabrafenib combination trametinib continuously stereotactic radiotherapy ( SRS ) melanoma brain metastasis . Stereotactic Radiosurgery ( SRS ) non-surgical radiation therapy use treat tumour brain . It deliver precisely target radiation . Currently SRS alone usual treatment patient 4 brain lesion . This study include 2 group 1 ) patient 1-4 brain lesion treat SRS concurrently dabrafenib trametinib 2 ) patient 5-10 brain lesion treat SRS concurrently dabrafenib trametinib .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Histologically confirm melanoma metastatic brain determine BRAF V600 mutationpositive . Age ≥ 18 year . ECOG performance status 0 1 ( Appendix I ) . Patients must life expectancy least 12 week . Presence measurable disease ( i.e . present least one measurable CNS lesion per RECIST 1.1 ) . Presence 110 brain metastasis confirm thin slice axial T1 postgadolinium MRI sequence . The maximum diameter single lesion ≤ 4 cm . All CNS metastasis amenable single fraction SRS fractionate SRS . Hemorrhagic lesion allow treat radiation oncologist deem lesion amenable focal SRS . Able swallow retain oral medication must clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . Laboratory requirement ( within 14 day prior registration ) : ANC ≥ 1.2 x 109/L Hemoglobin ≥ 90 g/L Platelet count ≥ 100 x 109/L PT/INR &amp; PTT ≤ 1.3 x ULN Total bilirubin ≤ 1.5 x ULN AST ALT ≤ 2.5 x ULN Serum creatinine ≤ 1.5 x ULN Creatinine Clearance ≥ 50 ml/min ( calculate Cockcroft Gault ) LVEF ≥ LLN ( within 28 day prior registration ) No prior treatment BRAF inhibitor MEK inhibitor . No known ocular primary mucosal melanoma . No prior systemic anticancer treatment ( chemotherapy , immunotherapy , biologic therapy , vaccine therapy , investigational treatment ) within last 2 week precede first dose combination . Patients must recover treatment related toxicity risk delay toxicity . Prior systemic treatment adjuvant setting allow . No current use prohibit medication No history malignancy confirm activate RAS mutation time . No history malignancy disease study within 3 year . No leptomeningeal metastasis metastasis cause spinal cord compression symptomatic untreated stable ≥ 3 month ( must document imaging ) . Subjects stable dose corticosteroid &gt; 2 week corticosteroid least 2 week enrol approval CCTG . No serious unstable preexist medical condition ( aside malignancy exception specify ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent , compliance study procedure . No history Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection ( subject laboratory evidence clear HBV and/or HCV permit ) . No history evidence cardiovascular risk ( see 4.2.10 detail ) . No history current evidence/risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) ( see 4.2.11 complete detail ) . No known immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate study treatment , excipients , and/or dimethyl sulfoxide ( DMSO ) . No pregnant lactate woman . No history interstitial lung disease active pneumonitis . Presence one metastases &gt; 4 cm maximal diameter . No prior whole brain radiation . No brainstem metastases . No contraindication MRI and/or Gadolinium contrast stereotactic brain radiation therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>